Supported
The cited record supports the material proposition.
Purdue said in November 2025 that the bankruptcy court would confirm its new plan, which provides about US$7.4 billion in cash to creditors.
today indicated it will approve the Chapter 11 Plan of Reorganization
- About
- Purdue Pharma L.P.
- Claim made by
- Purdue Pharma L.P., company statement
- Published
- 14 November 2025
- Evidence score
- 83 How it was scored
- Last reviewed
- 25 October 2026
Why this label
Purdue's release says the US Bankruptcy Court for the Southern District of New York indicated it would approve the plan, and that more than 99% of voting creditors supported itS4. The release gives about US$7.4 billion in cash, with the Sackler family contributing US$6.5 billion to US$7 billion over timeS4. A court filing cites the order confirming the plan, entered on 18 November 2025 in case 19-23649 (SHL) as ECF No. 8263S6. AP reported that Judge Sean Lane formally approved the plan that dayS7. Purdue permanently ceased operations on 1 May 2026, and Knoa Pharma began operating under a not-for-profit foundationS5. The order itself was not read. No appeal that undid the plan was found.
Current procedural position
Bankruptcy court indicated approval on 14 November 2025S4. Confirmation order entered on 18 November 2025, ECF No. 8263 in case 19-23649 (SHL)S6S7. Chapter 11 case concluded and Purdue ceased operations on 1 May 2026S5.
Record supporting the assessment
today indicated it will approve the Chapter 11 Plan of Reorganization
(Bankr. S.D.N.Y. Nov. 18, 2025), ECF No. 8263
A federal bankruptcy court judge on Tuesday formally approved OxyContin maker Purdue Pharma's plan
Purdue permanently ceased operations.
Conflicting or limiting record
No record located that conflicts with this assessment.
Evidence score: 83 of 100
The score grades how well the record establishes this assessment. It is not a score of Purdue Pharma L.P.. Score = source authority + directness + corroboration + procedural accuracy + currency + reproducibility.
| Component | Points | Max | Reason |
|---|---|---|---|
| Source authorityIs the source competent to establish the proposition? | 23 | 30 | A court filing cites the confirmation order, with company releases and AP in support. The order itself was not read. |
| DirectnessDoes the source state the proposition or only discuss adjacent facts? | 17 | 20 | The release states the court's indication and the amount. |
| CorroborationDo independent records support the same material point? | 13 | 15 | The court filing, AP and the company releases agree. |
| Procedural accuracyDoes the record settle the procedural state the claim describes? | 13 | 15 | The plan is confirmed and the case has concluded. |
| CurrencyHas the record been checked against later developments? | 9 | 10 | Checked to the April 2026 Knoa announcement. |
| ReproducibilityCan a reader locate the passage and repeat the assessment? | 8 | 10 | Both releases are public on Business Wire. |
| Total | 83 | 100 |
Timeline
Related cases
- Harrington, United States Trustee, Region 2 v. Purdue Pharma L.P.Supreme Court of the United States. Insolvency. 23-124.Stage: Decided on 27 June 2024, reversed and remanded.
- Nonconsensual third party releases not authorized, Second Circuit reversed, 5-4S3
Responses
- Purdue Pharma L.P., 14 November 2025: Purdue said the plan achieved remarkable consensus with more than 99% creditor support.S4
Revision history
- Assessment first published with label Supported.
Have a record that changes this assessment? See corrections and responses.
Sources
- S4Tier B Bankruptcy Court to Confirm Purdue Pharma’s Plan of ReorganizationPurdue Pharma L.P. via Business Wire. Company statement. 14 November 2025.Company account of the court's indication of approval and the plan amounts. It is not the confirmation order.
- S6Tier A Notice of Bankruptcy Court Order Confirming Bankruptcy Plan and Enjoining Continuation of Proceedings as to Debtor Purdue Pharma, L.P., Affiliated Debtors, and Related PartiesUS District Court for the Northern District of Ohio (notice filed by the Sackler parties in MDL No. 2804, hosted by NAAG). Court filing. 21 November 2025.Court filing that cites the confirmation order of 18 November 2025 in case 19-23649 (SHL), ECF No. 8263. It is a party notice, not the order itself.Link working, checked 25 October 2026
- S7Tier C Judge formally approves opioid settlement for Purdue Pharma and Sackler family members who own the companyAssociated Press (via PBS News). Press report. 18 November 2025.Report by Geoff Mulvihill that US Bankruptcy Judge Sean Lane formally approved the plan on 18 November 2025.Link working, checked 25 October 2026
- S5Tier B Knoa Pharma Begins Operations as a New, Public Health-Focused Company Dedicated to Supporting Patients and Abating the Opioid CrisisKnoa Pharma via Business Wire. Company statement. 30 April 2026.Successor company statement that Purdue ceased operations on 1 May 2026. The page shows no dateline, and the date is taken from the release URL.
- S3Tier A Harrington v. Purdue Pharma L.P., No. 23-124, slip opinionSupreme Court of the United States. Court judgment. 27 June 2024.Holds that nonconsensual releases of claims against nondebtors are not authorized. It does not address the later plan.Link working, checked 25 October 2026
Other claims about Purdue Pharma L.P.
- Contradicted88Purdue's original OxyContin label said that delayed absorption from OxyContin tablets was believed to reduce the drug's abuse liability.Official report, 31 July 20074 records citedProduct claims
- Supported87The US Justice Department said Purdue Pharma pleaded guilty in November 2020 to three federal felonies tied to its opioid marketing.Regulator statement, 24 November 20202 records citedFraud
- Outdated94Purdue said in May 2023 that the Second Circuit had upheld its plan of reorganization, which included releases of opioid claims against members of the Sackler family.Company statement, 30 May 20232 records citedCorporate status